Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PiSA: CYP3A Activity Study using Microdosed Midazolam
NCT03204578Phase 4Completed
- Sponsor
- University Hospital Basel
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of midazolam in Cytochrome P450 CYP3A enzyme deficiency, sponsored by University Hospital Basel. Primary endpoint: Area Under the Curve from 0 to 12 hours. Started Aug 2017; status: completed.
02
Drugs
midazolam
03
Conditions
Cytochrome P450 CYP3A enzyme deficiency
Beyond the preview
Go deeper on NCT03204578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204578.